Anti-γ-Catenin (Tyr-550), Phosphospecific Antibody

Plakoglobin (γ-Catenin) is a catenin family member identified as a component of desmosomes. γ-Catenin has high homology to β-catenin and, like β-catenin, it can associate with the cadherins, E-cadherin and N-cadherin. One molecule of α-catenin and at least one molecule of β-catenin and γ-Catenin simultaneously bind to a single cadherin molecule. A 19-amino acid sequence of desmoglein was found to be critical for binding of γ-Catenin. Similar catenin-binding domains found in cadherins, suggest a common mechanism for γ-Catenin localization to both adherens junctions and desmosomes. Phosphorylation of tyrosine residues in γ-Catenin can modify its interactions with other proteins. Phosphorylation of tyrosine 644 decreases γ-Catenin association with α-catenin, but increases binding to desmoplakin. Fer kinase can phosphorylate tyrosine 550, which increases γ-Catenin binding to α-catenin. Thus, tyrosine phosphorylation may be important for regulation of γ-Catenin protein-protein interactions within desmosomal complexes.

Our γ-Catenin (Tyr-550) rabbit polyclonal phosphospecific primary antibody from PhosphoSolutions is produced in-house. It detects human, mouse, and rat γ-Catenin (Tyr-550) and is antigen affinity purified. It is great for use in WB, ICC.

Phospho-γ-Catenin (Tyr-550) synthetic peptide (coupled to KLH) corresponding to amino acid residues around tyrosine 550 of human γ-Catenin. This peptide sequence is highly conserved in rat and mouse γ-Catenin.

For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.

This antibody was cross-adsorbed to both phospho-tyrosine coupled to agarose and to dephosphorylated γ-Catenin (Tyr-550) peptide before affinity purification using phospho-γ-Catenin (Tyr-550) peptide (without carrier) . The antibody detects an 84kDa* protein corresponding to the molecular mass of γ-Catenin on SDS-PAGE immunoblots of A431 and Hct116 src transformed cells treated with pervanadate (1 mM for 30 min), but not in control cells.